[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,144,900
  • Shares Outstanding, K 722,323
  • Annual Sales, $ 8,260 K
  • Annual Income, $ -299,770 K
  • EBIT $ -1,366 M
  • EBITDA $ -1,363 M
  • 60-Month Beta 1.12
  • Price/Sales 3,213.73
  • Price/Cash Flow N/A
  • Price/Book 5.40

Options Overview Details

View History
  • Implied Volatility 43.69% (-2.52%)
  • Historical Volatility 35.30%
  • IV Percentile 21%
  • IV Rank 21.28%
  • IV High 87.70% on 02/11/26
  • IV Low 31.79% on 10/03/25
  • Expected Move (DTE 21) 2.81 (7.97%)
  • Put/Call Vol Ratio 4.53
  • Today's Volume 83
  • Volume Avg (30-Day) 3,397
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 70,300
  • Open Int (30-Day) 57,200
  • Expected Range 32.51 to 38.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.52
  • Number of Estimates 1
  • High Estimate $-0.52
  • Low Estimate $-0.52
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.47 +9.12%
on 08/03/26
37.97 -6.69%
on 08/19/26
+1.59 (+4.70%)
since 07/28/26
3-Month
27.92 +26.88%
on 06/02/26
37.97 -6.69%
on 08/19/26
+5.55 (+18.57%)
since 05/28/26
52-Week
11.85 +198.99%
on 08/29/25
37.97 -6.69%
on 08/19/26
+23.49 (+196.73%)
since 08/28/25

Most Recent Stories

More News
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune disease LISRAYA is a once-daily pill that directly targets...

ROIVW : 2.75 (-3.85%)
ROIV : 35.64 (-5.16%)
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib)...

ROIV : 35.64 (-5.16%)
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune disease LISRAYA is a once-daily pill that directly targets...

ROIVW : 2.75 (-3.85%)
ROIV : 35.64 (-5.16%)
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of...

ROIV : 35.64 (-5.16%)
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

JAMA Dermatology  publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions...

ROIVW : 2.75 (-3.85%)
ROIV : 35.64 (-5.16%)
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

JAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg...

ROIV : 35.64 (-5.16%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat...

IMVT : 41.90 (-4.38%)
ROIV : 35.64 (-5.16%)
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU)...

ROIVW : 2.75 (-3.85%)
ROIV : 35.64 (-5.16%)
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase...

ROIVW : 2.75 (-3.85%)
ROIV : 35.64 (-5.16%)
Roivant's Pipeline Transparency Test Arrives as Brepocitinib Nears Its First Commercial Moment

Barchart Research What to Expect from ROIV Earnings ROIV Generated August 5, 2026 Current Price $34.60 EPS Estimate $$-0.45 Consensus Rating Strong Buy Average Move 7.24% Roivant's Pipeline Transparency...

ROIV : 35.64 (-5.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 39.40
2nd Resistance Point 38.61
1st Resistance Point 38.09
Last Price 35.64
1st Support Level 36.78
2nd Support Level 35.99
3rd Support Level 35.47

See More

52-Week High 37.97
Last Price 35.64
Fibonacci 61.8% 27.99
Fibonacci 50% 24.91
Fibonacci 38.2% 21.83
52-Week Low 11.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.